SCHEMBL10003080

SCHEMBL10003080

Cc1nc2c(cc1NC(=O)c1ccc(F)cc1)c(OCC(F)(F)F)c(C(=O)O)n2C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.42
▸ POLB P06746 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ MAPT P10636 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ KCNK2 O95069 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ NTRK1 P04629 1/20 0.37
▸ KCNMA1 Q12791 1/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ CSNK1D P48730 1/20 0.36
▸ CSNK1E P49674 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ P2RY14 Q15391 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ PDE5A O76074 1/20 0.36
▸ MRGPRX1 Q96LB2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003390 0.93 HTT (0.41) ALDH1A1POLBLMNAMAPTMEN1
SCHEMBL10003698 0.91 KDM4E (0.48) ALDH1A1POLBLMNAKDM4EMAPT
SCHEMBL10004018 0.89 ALDH1A1 (0.41) ALDH1A1POLBLMNAKDM4EMAPT
SCHEMBL10003177 0.84 SMN1; SMN2 (0.43) ALDH1A1POLBLMNAKDM4EMAPT
SCHEMBL10002795 0.84 BRPF1 (0.40) LMNAKDM4EMAPTTHRBMEN1
SCHEMBL10003062 0.82 LMNA (0.46) ALDH1A1POLBLMNAKDM4EMAPT
SCHEMBL10003793 0.82 SMO (0.49) ALDH1A1POLBMEN1KMT2ATSHR
SCHEMBL10003404 0.81 HTT (0.40) ALDH1A1LMNAKDM4EMAPTMEN1
SCHEMBL10003167 0.81 F10 (0.40) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL10003568 0.80 NPC1 (0.44) ALDH1A1LMNAKDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH ALDH1A1 321/4885POLB 4723/4885LMNA 4452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback